Customer Interaction Solutions
Gilead Announces New Agreement with Medicines Patent Pool for Access...
Gilead Sciences, Inc. announced today at the 20th International AIDS Conference in Melbourne, Australia, a new agreement with the Medicines Patent Pool to expand access to Gilead's investigational drug tenofovir alafenamide for HIV and hepatitis B, contingent on the medicine's U.S. regulatory approval.
Many People With HIV Could Switch to Newer, Safer Regimens
A majority of people taking antiretrovirals to treat HIV could switch to newer regimens with improved side effect profiles, according to an analysis of Australians living with the virus, aidsmap reports.
Therapy with newer, safer antiretrovirals an option for the majority of HIV-positive patients
The majority of patients taking antiretroviral therapy that includes drugs associated with long-term side-effects may have the option of switching to a novel regimen that uses newer and safer anti-HIV drugs, according to Australian research published in PLOS One.
Pharma Marketing Blog
Has Gilead's Director of Regulatory Affairs Been Hiding Under a...
At the end of June, the FDA sent a Notice of Violation letter to Naumann Chaudry, Director, Regulatory Affairs Advertising and Promotion at Gilead Sciences, citing a sponsored link on Google for VIREAD .
Stribild is a fixed-dose tablet combining 150mg elvitegravir, 200mg emtricitabine, and 245mg tenofovir disoproxil, along with 150mg cobicistat, a boosting agent.